Nautilus Biotechnology, Inc.
NAUT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $28 | $19 | $115 | $186 |
| Short-Term Investments | $102 | $154 | $70 | $160 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $3 | $3 | $3 | $3 |
| Total Curr. Assets | $133 | $177 | $187 | $349 |
| Property Plant & Equip (Net) | $32 | $37 | $33 | $32 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $76 | $91 | $129 | $16 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $110 | $129 | $163 | $49 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $243 | $306 | $350 | $398 |
| Liabilities | – | – | – | – |
| Payables | $1 | $2 | $1 | $2 |
| Short-Term Debt | $4 | $4 | $2 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $3 | $4 | $4 | $3 |
| Total Curr. Liab. | $8 | $9 | $7 | $6 |
| LT Debt | $26 | $31 | $28 | $29 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $26 | $31 | $28 | $29 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $30 | $35 | $30 | $30 |
| Total Liabilities | $34 | $40 | $35 | $35 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$273 | -$202 | -$139 | -$81 |
| AOCI | $0 | -$0 | -$2 | -$0 |
| Other Equity | $482 | $468 | $455 | $444 |
| Total Equity | $209 | $265 | $315 | $364 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $243 | $306 | $350 | $398 |
| Net Debt | $3 | $15 | -$84 | -$156 |